Sirion Therapeutics (drug rights) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
Sirion Therapeutics (drug rights) General Information
Description
United States rights for DUREZOL and emulsion and global rights for ZYCLORIN. DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. ZYCLORIN is a topical ophthalmic immunomodulator and immunosuppressive agent.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Primary Office
- 3110 Cherry Palm Drive
- Suite 340
- Tampa, FL 33619
- United States
Sirion Therapeutics (drug rights) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.
Request a free trialSirion Therapeutics (drug rights) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.
Request a free trial